

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0108
Drug name and formulations:		Levonorgestrel IUS (Kyleena®)
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Similar side effect profile to other LNG-IUS
Clinical effectiveness	<i>Established licensed product</i>	Established. Contraceptive effectiveness is comparable to other available LNG-IUS
Strength of evidence		Robust
Patient factors	<i>Published patient factors</i>	Placement rated as ‘easy’, less pain than Mirena®
Cost effectiveness or resource impact	£	Cost effective compared to alternatives
Place of therapy relative to available treatments	<i>1/2nd tier</i>	2 nd line
National guidance and priorities	<i>NICE, MTRAC</i>	SMC approved
Local health priorities	<i>CCG views</i>	CCGs supportive
Equity of access	<i>Equality assessment</i>	n/a
Stakeholder views	<i>Define wider groups to be engaged</i>	n/a
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	Not required
Prescribing data	<i>Requires 12 months primary or secondary care data</i>	Not required

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Approved Green
Implementation requirements:	
Implementation monitoring e.g. prescribing data:	